I don’t find 2024 up on youtube yet, but hopefully it will appear.

1 Like

Thanks for sharing. The most interesting part for me was:

Associations of various factors with organ-specific aging can be measured. Smoking, unsurprisingly, is associated with increased aging in all organs. Alcohol consumption, on the other hand, produced mixed results: while it’s obviously bad for kidneys and the intestine, it’s good for the lungs and arteries.

2 Likes

Weird that the effect of alcohol on the liver is so variable (and neutral on average). Perhaps it was the low dose.

The liver is better at regeneration. I think this is probably because it takes a lot of citrate from serum through the SLC13A5 citrate carrier.

I am interested in the question of the balance of harm from acetaldehyde and ethanol. Acetate is generally good although I would always be careful consuming too many naked protons.

More recently I have been in the habit of taking 2-3g of panetethine, 1g of DHM and 200mg of melatonin just as i start drinking.

I think this reduces quite a bit of harm.

3 Likes

See this thread - Alex has posted some of the videos on his company YouTube account:

Some of the newly posted videos I find interesting, from the 2024 ARDD conference. They seem to be adding more of the vides every few days. See here for the latest list: https://www.youtube.com/@ardd3628/videos

3 Likes

Anything to report? Interesting findings or changes in your thinking?

Saul Villeda talks about unpacking plasma to discover the parts that show rejuvenation potential, in particular for the brain.

Johan Luthman’s talk seems to be mostly about how things break in the brain, but he does have some optimism for drugs that can help.

Hal Gunn thinks that the innate immune system can be improved by something resembling generic vaccination. It will be interesting to see if it pans out.

Maiken Nedergaard gives some details on why sleep is good, esp for preventing dementia.

Chris Reading reports that Bezisterim seems to be the latest cool drug for brain functions.

The first talks seem to be a lot about the brain.

3 Likes

i like this one “Improved resilience and proteostasis mediate longevity upon Daf-2 degradation in old age” By Collin Ewald.

.
They doubled the total lifespan in some individuals with late life interventions. Which is comparable to double the total lifespan in humans of 90 -100-year-old humans.

It made me think of the importance of proteostasis

3 Likes
2 Likes

Another very good presentation… with lots of discussion of rapamycin and mTOR, biological clocks and inflammation.

Interesting NHANEs results… people who take medications (to lower lipids, get blood glucose levels in line, etc.) have basically the same longevity results (or even better) as those who are “optimal” and don’t need the medications.

Interestingly Urolithin-A stimulates autophagy and down regulates mTOR

and at 22:15 Brian Kennedy mentions:

Rapamycin at least in Mouse our Mouse models does not adversely affect muscle function with age it’s preserving stem cell function in muscles and actually the mice are by most measures are doing at least as as well as the control animals

Brian Kennedy at ARDD2024: Where are we in the Longevity Quest

6 Likes

Thank you, RapAdmin, that’s a fabulous video from Brian Kennedy. You picked a great set of graphs from that video showing survival curves for optimal biomarkers, borderline, require treatment, but just a few seconds later the graph becomes even better (~14:30), where we also see the labels, and the treated (polypill) show a beautiful line, the best of 'em.

A couple of casual observations. BK mentions that they’ve had very limited luck combining longevity treatments, because so often those don’t stack, or even cancel each other. Now, those are focused on longevity specifically. But, if we look at treatments that address diseases and therefore prolong life through those means, then the polypill comes out as a kind of star, looking at that graph, pretty robust. And a polypill is a “combination” if there ever was one. Of course one could say that disease treatment is not strictly a longevity intervention, as really in treating disease it merely normalizes lifespan, bringing it back to what it would be without disease, i.e., it abolishes the life-shortening effect of disease. And yes, that is true to an extent, but not entirely, because as the graph shows, treated subjects can exceed the survival of naturally “optimal”, who are of course free friom disease. That shows a small, but significant longevity effect - therefore the polypill qualifies as a true longevity treatment (though clearly rather modest).

This also validates the approach many of us on this site take to medications. We take them, believing that the net effect will be positive. The opposing view - well represented here too - is that it is best to reach optimal biomarkers through lifestyle interventions only, without drugs. It’s what I call the naturalistic fallacy. The superstition, essentially, that somehow “natural” is always superior to the “chemical”, “artificial”, “drugs”, “pharma” and so on. I always saw that as a pernicious idea, because it is the most natural thing in the world to look at results, regardless of how you got there, through “natural” or “unnatural” means. Who cares if you die “naturally” at 85, but live healthily but “unnaturally” to 105. I’ll take the “unnatural” 105 over the “natural” 85 every time. “Unnatural” is the very definition of how civilization is built and progresses. If we only strictly ever adhered to “natural” we’d not only not emerge from the caves, but we wouldn’t even climb down from the trees. Evolve or join the dinosaurs. Science for the win!

Therefore, I for one, have no hesitation about taking pharmaceuticals. So happens, that my lipids are “naturally” trash (despite heroic lifestyle interventions), and so I must take lipid lowering pharma agents. But I’d take statins even if my lipids were “naturally good”, because of the pleiotropic effects anyway - they lower inflammation, which has good health effects. And that way, I get both “good” lipid numbers (as good as “naturally” optimal ones), but in addition might get benefits from the anti-inflammatory or anti-cancer effects. Win-win. Same for my borderline blood sugar. I take empagliflozin, banking that not only will it help my BG biomarker, but perhaps have additional pleiotropic effects (perhaps on kidney health?).

Obviously, what matters here is a careful tailoring of what is in that polypill. Some BP meds are better than others for longevity - and some may even be deleterious. So, in picking my BG, BP, and ApoB polypill, I have to look very carefully at the individual constituents. That’s where the concern of DDI (drug-drug interactions) enters. The dangers of polypharmacy. Yes, it’s something to be concerned with - absolutely. But as this presentation shows, the mere fact of polypharmacy is not deleterious in and of itself - there is room for a sum greater than its parts, because that’s what the polypill result shows us.

Therefore, what we can take away from this is: if you have borderline metabolic biomarkers, it is OK for you to resort to a polypill, as long as you carefully select the constituent ingredients suitable to your unique situation. There is no one size fits all here - some people do better with one drug than another, or have a negative reaction or whatnot. But there is hope - you can go forward with drugs as long as you carefully vet your particular polypill. Or at least that’s what I took from this. YMMV.

4 Likes

Yes, A great talk. What struck me was:

  • His statement that we can hit pathways too hard and that hitting, for example, mTOR too hard with 20 interventions might be detrimental. (think Brian Johnsson)

  • The effects of Urolithin A

  • And what are considered normal biomarkers might not be optimal biomarkers. But require medication or lifestyle interventions.

Conclusion:

  • Reduce supplements even more,
  • Consider Urulithin A, as a part of a reduced stack.
  • Be aggressive when it comes to what are optimal biomarkers (not normal Biomarkers)
6 Likes

Working out synergy without mechanisms is basically pot luck.

2 Likes

To what degree does the urolithin A anti-aging pathway overlap wth rapamycin? In other words, if you are already taking rapamycin, (1) should you be taking UA instead, (2) if taking both, are they complementary, or adversarial (3) if taking both, are you hitting mTOR too much (4) is UA more suitable for some people vs others, (5) has UA been as validated as rapa for lifespan and/or healthspan? I ask, because I’m not up on all the UA research, but seem to recall that depending on your gut biome, you may or may not get UA from food. TIA!

1 Like

What i intend doing is experimenting with a high dose of UA whilst wearing a CGM to see if there is a glucose effect. If UA operates through mTOR then it should be comparable to rapamycin.

4 Likes

A valid remark. I have similar questions regarding berberine which I take (and, to some degree, metformin, which I don’t take). Does a constantly activated AMPK inhibit mTOR too much? So I have lowered my dose of rapamycin.

I don’t take UA, At least not yet. But it looks like a supplement that has a sound scientific base. I eat walnuts and pomegranate extracts, so I might get it through conversion from gut microbes, if they are of the right kind.

I will revise my interventions before the start of 2025. I do that on a frequent basis but the start of a new year is a time for deeper reflections. It would be nice to have a new thread here, that brings light on how we will start 2025 when it comes to our anti-aging interventions.

1 Like

This is right but “optimal” might be unique to each person. I’ve given up thinking I can analyze myself into optimal fitness. Since exercise is good for everything I spend my time planning and doing a comprehensive range of physical activities and expanding my body’s range of adaptive homeostasis. And some other stuff.

2 Likes

Is the a clock / calculator using these factors available to the public?

Here is Dr Kennedy’s quote in support of your (and my) conclusion on supplement stack size

“When we combine things together are we hitting the same pathway … are we hitting it better or too hard? Are we hitting combined pathways that work together? We don’t have the rules for this right now. So when people are out there combining multiple things together…. I say this all the time if you are taking 20 different things it’s like mixing 20 colors of paint. At the end of the day you’re going to get some ugly brown outcome probably. And so we really have to be careful with that because I can’t tell you what 3 things to take together.”

Dr Kennedy has been saying this for some time. It’s one of the reasons I’ve moved toward fewer chemical interventions. Hopefully I’m picking the best ones for me (my goals, my genetics, my health status).

5 Likes